US2003186886A1PendingUtilityA1

Treating eye disorders using intestinal trefoil proteins

61
Priority: Apr 12, 1996Filed: May 30, 2003Published: Oct 2, 2003
Est. expiryApr 12, 2016(expired)· nominal 20-yr term from priority
Inventors:Daniel Podolsky
A61K 38/00C07K 14/575
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Intestinal trefoil factors and nucleic acids encoding intestinal trefoil factors are disclosed. The intestinal trefoil factors disclosed are resistant to destruction in the digestive tract and can be used for the treatment of peptic ulcer diseases, inflammatory bowel diseases, eye disorders and other insults.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating an eye disorder in a patient, said method comprising administering to the eye of said patient a trefoil protein selected from the group consisting of intestinal trefoil factor (ITF), spasmolytic peptide (SP), pS2, and biologically active fragments thereof.  
     
     
         2 . The method of  claim 1 , wherein said trefoil protein is a human trefoil protein.  
     
     
         3 . The method of  claim 2 , wherein said trefoil protein is intestinal trefoil factor (ITF) or a biologically active fragment thereof.  
     
     
         4  The method of  claim 1 , wherein said eye disorder is selected from the group consisting of superficial punctate keratitis, herpes simplex keratoconjunctivitis, ophthalmic herpes zoster, phlyctenular keratoconjunctivitis, keratoconcus, and cicatricial penhigoid.  
     
     
         5 . The method of  claim 1 , wherein said eye disorder is caused by an infection of a bacteria, virus, or fungi.  
     
     
         6 . The method of  claim 5 , wherein said virus is selected from the group consisting of an adenovirus and a herpes simplex virus.  
     
     
         7 . The method of  claim 1 , wherein said eye disorder is inflammation of the conjunctival epithelium.  
     
     
         8 . The method of  claim 1 , wherein said eye disorder is inflammation of the scleral epithelium.  
     
     
         9 . A method for treating keratoconjunctivitis sicca (dry eyes) in a patient, said method comprising administering to the eye of said patient a trefoil protein selected from the group consisting of intestinal trefoil factor (ITF), spasmolytic peptide (SP), pS2, and biologically active fragments thereof.  
     
     
         10 . The method of  claim 9 , wherein said trefoil protein is a human trefoil protein.  
     
     
         11 . The method of  claim 10 , wherein said trefoil protein is intestinal trefoil factor (ITF) or a biologically active fragment thereof.

Join the waitlist — get patent alerts

Track US2003186886A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.